Cargando…

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers

The clinical treatment of DNA-repair defective tumours has been revolutionised by the use of poly(ADP) ribose polymerase (PARP) inhibitors. However, the efficacy of these compounds is hampered by resistance, which is attributed to numerous mechanisms including rewiring of the DNA damage response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayley, Rachel, Sweatman, Ellie, Higgs, Martin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099596/ https://www.ncbi.nlm.nih.gov/pubmed/37065862 http://dx.doi.org/10.20517/cdr.2022.73

Ejemplares similares

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
por: Sadida, Hana Q., et al.
Publicado: (2023)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Parenthood and Cross-Border Surrogacy: What Is ‘New’? The ECtHR’s First Advisory Opinion
por: Margaria, Alice
Publicado: (2020)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

Histone Modifications: Epigenetic Mediators of Environmental Exposure Memory
por: Camacho, Jessica, et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
por: Furuse, Junji
Publicado: (2019)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
por: Giudice, Elena, et al.
Publicado: (2023)

The PARP Way to Epigenetic Changes
por: Ummarino, Simone, et al.
Publicado: (2021)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

Behavior Modification: A Patient and Physician’s Perspective
por: Swanson, Elizabeth, et al.
Publicado: (2017)

Pulmonary and renal protection: targeting PARP to ventilator-induced lung and kidney injury?
por: Matejovic, Martin, et al.
Publicado: (2010)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

H3K4 methylation by SETD1A/BOD1L facilitates RIF1-dependent NHEJ
por: Bayley, Rachel, et al.
Publicado: (2022)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
por: Sun, Chong-kui, et al.
Publicado: (2014)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

A decade of clinical development of PARP inhibitors in perspective
por: Mateo, J, et al.
Publicado: (2019)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
por: Mani, Chinnadurai, et al.
Publicado: (2021)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5aocno290qlnleuh6ij08snpbq